Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
AVNR's Cash to Debt is ranked higher than
98% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. AVNR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
AVNR' s 10-Year Cash to Debt Range
Min: 0.5  Med: 21.59 Max: No Debt
Current: No Debt
Equity to Asset 0.89
AVNR's Equity to Asset is ranked higher than
91% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. AVNR: 0.89 )
Ranked among companies with meaningful Equity to Asset only.
AVNR' s 10-Year Equity to Asset Range
Min: -0.08  Med: 0.66 Max: 0.92
Current: 0.89
-0.08
0.92
F-Score: 6
Z-Score: 57.06
M-Score: -1.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -40.29
AVNR's Operating margin (%) is ranked lower than
87% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. AVNR: -40.29 )
Ranked among companies with meaningful Operating margin (%) only.
AVNR' s 10-Year Operating margin (%) Range
Min: -1373.1  Med: -329.33 Max: 35.08
Current: -40.29
-1373.1
35.08
Net-margin (%) -43.85
AVNR's Net-margin (%) is ranked lower than
88% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. AVNR: -43.85 )
Ranked among companies with meaningful Net-margin (%) only.
AVNR' s 10-Year Net-margin (%) Range
Min: -1389.34  Med: -251.42 Max: 1.84
Current: -43.85
-1389.34
1.84
ROE (%) -63.82
AVNR's ROE (%) is ranked lower than
90% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. AVNR: -63.82 )
Ranked among companies with meaningful ROE (%) only.
AVNR' s 10-Year ROE (%) Range
Min: -3615.78  Med: -110.46 Max: 1.02
Current: -63.82
-3615.78
1.02
ROA (%) -39.01
AVNR's ROA (%) is ranked lower than
90% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. AVNR: -39.01 )
Ranked among companies with meaningful ROA (%) only.
AVNR' s 10-Year ROA (%) Range
Min: -181.93  Med: -68.02 Max: 0.92
Current: -39.01
-181.93
0.92
ROC (Joel Greenblatt) (%) -1416.29
AVNR's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. AVNR: -1416.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AVNR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7121.42  Med: -1824.46 Max: 575.06
Current: -1416.29
-7121.42
575.06
Revenue Growth (3Y)(%) 99.10
AVNR's Revenue Growth (3Y)(%) is ranked higher than
98% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. AVNR: 99.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AVNR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -9.10 Max: 160.4
Current: 99.1
0
160.4
EBITDA Growth (3Y)(%) -17.60
AVNR's EBITDA Growth (3Y)(%) is ranked lower than
79% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. AVNR: -17.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AVNR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -16.60 Max: 223.2
Current: -17.6
0
223.2
EPS Growth (3Y)(%) -15.30
AVNR's EPS Growth (3Y)(%) is ranked lower than
73% of the 451 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. AVNR: -15.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AVNR' s 10-Year EPS Growth (3Y)(%) Range
Min: -67.9  Med: -4.70 Max: 238.4
Current: -15.3
-67.9
238.4
» AVNR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AVNR Guru Trades in Q2 2014

Steven Cohen 201,800 sh (unchged)
» More
Q3 2014

AVNR Guru Trades in Q3 2014

Louis Moore Bacon 100,000 sh (New)
Chuck Royce 1,289,100 sh (New)
Paul Tudor Jones 127,470 sh (New)
Jim Simons 58,014 sh (New)
Leon Cooperman 100,000 sh (New)
Steven Cohen 498,500 sh (+147.03%)
» More
Q4 2014

AVNR Guru Trades in Q4 2014

Mario Gabelli 493,524 sh (New)
Jim Simons 884,514 sh (+1424.66%)
Louis Moore Bacon 150,000 sh (+50.00%)
Louis Moore Bacon 150,000 sh (unchged)
Leon Cooperman Sold Out
Steven Cohen Sold Out
Chuck Royce 405,100 sh (-68.57%)
Paul Tudor Jones 22,895 sh (-82.04%)
» More
Q1 2015

AVNR Guru Trades in Q1 2015

Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
Jim Simons Sold Out
Chuck Royce Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AVNR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 12.03
AVNR's P/B is ranked lower than
91% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. AVNR: 12.03 )
Ranked among companies with meaningful P/B only.
AVNR' s 10-Year P/B Range
Min: 0.78  Med: 11.24 Max: 202.67
Current: 12.03
0.78
202.67
P/S 23.89
AVNR's P/S is ranked lower than
92% of the 649 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. AVNR: 23.89 )
Ranked among companies with meaningful P/S only.
AVNR' s 10-Year P/S Range
Min: 2.23  Med: 19.41 Max: 119.75
Current: 23.89
2.23
119.75
Current Ratio 9.37
AVNR's Current Ratio is ranked higher than
89% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. AVNR: 9.37 )
Ranked among companies with meaningful Current Ratio only.
AVNR' s 10-Year Current Ratio Range
Min: 0.35  Med: 4.14 Max: 10.96
Current: 9.37
0.35
10.96
Quick Ratio 9.35
AVNR's Quick Ratio is ranked higher than
90% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. AVNR: 9.35 )
Ranked among companies with meaningful Quick Ratio only.
AVNR' s 10-Year Quick Ratio Range
Min: 0.29  Med: 4.13 Max: 10.96
Current: 9.35
0.29
10.96
Days Inventory 71.36
AVNR's Days Inventory is ranked higher than
73% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.49 vs. AVNR: 71.36 )
Ranked among companies with meaningful Days Inventory only.
AVNR' s 10-Year Days Inventory Range
Min: 0.73  Med: 125.63 Max: 27314.17
Current: 71.36
0.73
27314.17
Days Sales Outstanding 72.45
AVNR's Days Sales Outstanding is ranked higher than
50% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.86 vs. AVNR: 72.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVNR' s 10-Year Days Sales Outstanding Range
Min: 3.38  Med: 39.09 Max: 73.25
Current: 72.45
3.38
73.25

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -1.50
AVNR's Earnings Yield (Greenblatt) (%) is ranked lower than
76% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. AVNR: -1.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AVNR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -1.5  Med: 332.10 Max: 2474.1
Current: -1.5
-1.5
2474.1

Analyst Estimate

Sep15 Sep16
Revenue(Mil) 23 100
EPS($) -4.56 -3.55
EPS without NRI($) -4.56 -3.55

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:AV2B.Germany,
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.
» More Articles for AVNR

Headlines

Articles On GuruFocus.com
Gabelli's Q4 Picks Include Acquisition Targets Feb 06 2015 
A Look at Leon Cooperman's Most Performing Recent Buys Jan 30 2015 
Weekly CEO Sells Highlight: Danaher Corporation, Orbitz Worldwide Inc., 3D Systems Corporation and A May 20 2013 
Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 
Options V: Short-Term Strategy – Earning Money on Volatility Oct 19 2011 
Avanir Pharmaceuticals Reports Operating Results (10-Q) Feb 07 2011 
Avanir Pharmaceuticals Reports Operating Results (10-K) Dec 08 2010 
Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 195,300 Shares Dec 03 2010 
Weekly CEO Sells Highlights: MAC, GNET, ASIA, and AVNR Sep 05 2010 
Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 102,874 Shares Sep 02 2010 

More From Other Websites
Avanir Pharmaceuticals Announces New Findings from Dementia/Alzheimer's Disease Cohort of PRISM II... Jul 23 2015
Avanir Pharmaceuticals Announces New Findings from Dementia/Alzheimer's Disease Cohort of PRISM II... Jul 23 2015
/C O R R E C T I O N -- Avanir Pharmaceuticals, Inc./ Jun 30 2015
/C O R R E C T I O N -- Avanir Pharmaceuticals, Inc./ Jun 30 2015
Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II... Jun 30 2015
Avanir Pharmaceuticals Announces Publication of Positive Phase IIIb Results from AVP-825... Jun 17 2015
Avanir Pharmaceuticals Announces Publication of Positive Phase IIIb Results from AVP-825... Jun 17 2015
Avanir Pharmaceuticals Announces Presentation of Survey Evaluating the Prevalence of Pseudobulbar... May 05 2015
Avanir Pharmaceuticals Announces Presentation of Survey Evaluating the Prevalence of Pseudobulbar... May 05 2015
Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA),... May 01 2015
Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA),... May 01 2015
Avanir Pharmaceuticals Announces Multiple Data Presentations Highlighting Its Central Nervous System... Apr 15 2015
Avanir Pharmaceuticals Announces Multiple Data Presentations Highlighting Its Central Nervous System... Apr 15 2015
Football Hall-of-Famer Barry Sanders Tackles Pseudobulbar Affect; A Little-known But Widespread... Jan 21 2015
AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Jan 13 2015
Otsuka Pharmaceutical Completes Acquisition of Avanir Pharmaceuticals (119KB) Jan 13 2015
Avanir reports 4Q loss Jan 05 2015
Avanir reports 4Q loss Jan 05 2015
AVANIR PHARMACEUTICALS, INC. Financials Dec 17 2014
Otsuka Pharmaceutical Commences Tender Offer to Acquire All Outstanding Shares of Avanir... Dec 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK